Alvotech NASDAQ: ALVO Chief Strategy Officer Balaji Prasad said the biosimilar developer is preparing to resubmit three biologics license applications to the U.S. Food and Drug Administration in June after addressing manufacturing observations that led to complete response letters for pipeline products. Speaking with BofA Securities pharma and biotech analyst Jason Gerberry at the BofA Annual Healthcare Conference, Prasad said the company has been commercial in the U.S. market since the launch of its biosim ...